Lorvotuzumab mertansine
Wikipedia on Answers.com:
Top
Lorvotuzumab mertansine
 |
|
|---|---|
| Monoclonal antibody | |
| Type | Whole antibody |
| Source | Humanized |
| Target | CD56 |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 1008106-64-6  |
| ATC code | None |
| UNII | 0IVD6ASY0W |
| KEGG | D09927 |
| Chemical data | |
| Formula | ? |
 (what is this?) (verify) |
|
Lorvotuzumab mertansine (IMGN901) is an antibody-drug conjugate of lorvotuzumab linked to mertansine intended for CD56 positive cancers (e.g. small-cell lung cancer, ovarian cancer).[1][2]
It has been granted Orphan drug status for Merkel cell carcinoma.[3]
It has reported encouraging Phase II results for small-cell lung cancer.[4]
References
- ^ Dimond (9 Mar 2010). "Antibody-Drug Conjugates Stage a Comeback". http://www.genengnews.com/analysis-and-insight/antibody-drug-conjugates-stage-a-comeback/77899350/.
- ^ ImmunoGen reports encouraging clinical data of IMGN901. News-medical.net. Retrieved on 2010-11-20.
- ^ http://www.news-medical.net/news/20100308/ImmunoGen-receives-FDA-orphan-drug-designation-for-IMGN901-compound-in-treatment-of-MCC.aspx
- ^ "ImmunoGen Announces Encouraging New Clinical Data With The Company’s IMGN901 Compound In The Treatment Of Small-Cell Lung Cancer". 2009. http://lungcancer.nocancersite.com/html/2011/02/1745.html.
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
Post a question - any question - to the WikiAnswers community:
Copyrights:
Wikipedia on Answers.com
This article is licensed under the Creative Commons Attribution/Share-Alike License. It uses material from the Wikipedia article Lorvotuzumab mertansine.
Read more